Uncategorized Archives - Status of COVID-19 Vaccine Development

The table below shows the vaccines that have been authorized for use around the world, as of April 11, 2021. The letter “A” indicates that the vaccine has been authorized only for emergency, early, or limited use in a location. The letter “B” indicates that the vaccine has received full market approval in a location.

Location	Pfizer/BioNTech (BTN-162b2)	Moderna (mRNA-1273)	Janssen (Johnson & Johnson)	Gamaleya Research Institute (Sputnik V)	AstraZeneca Oxford (AZD1222)	Sinovac (CoronaVac)	SinoPharm (BBIBP-CorV)	Bharat Biotech (Covaxin)	Bektop (EpiVacCorona)	CanSinoBio (Convidecia; Also known as: Ad5-nCoV)	Wuhan Institute	CoviVac	Anhui Zhifei Longcom (ZF2001)
Algeria				A	A
Angola				A
Antigua and Barbuda				A
Argentina	A			A	A		A
Armenia				A
Australia	A				A
Azerbaijan				A		A
Bahamas					A
Bahrain	B		A	A	A		B
Bangladesh					A
Barbados					A
Belarus				A
Bhutan					A
Bolivia				A
Bosnia and Herzegovina				A
Botswana	A				A
Brazil	B		A		B	A
Cambodia						A	A
Cameroon				A
Canada	A	A	A		A
Chile	A				A	A
China						B	B			A	A		A
Colombia	A		A		A	A
Congo Republic				A
Costa Rica	A
Djibouti				A
Dominican Republic					A
Ecuador	A					A
Egypt				A	A		A
El Salvador					A
European Union	A	A	A		A
Gabon				A
Ghana				A	A
Greenland	A
Guatemala				A
Guinea				A
Guyana				A
Honduras				A
Hong Kong	A					A
Hungary				A	A
Iceland	A	A	A		A
India					A			A
Indonesia					A	A
Iran				A	A		A	A
Iraq	A			A	A		A
Israel	A	A
Japan	A
Jordan	A			A			A
Kazakhstan				A
Kenya				A	A
Kuwait	A				A
Kyrgyzstan				A
Laos				A		A
Lebanon	A			A
Liechtenstein			A		A
Malaysia	A				A	A
Maldives					A		A
Mali				A
Mauritius				A				A
Mexico	A			A	A	A				A
Moldova	A			A	A
Monaco	A
Mongolia	A	A		A	A
Montenegro				A
Morocco				A	A
Myanmar				A
Namibia				A
Nepal					A		A	A
New Zealand	B
Nicaragua				A
Nigeria					A
North Macedonia				A
Norway	A	A	A		A
Oman	A
Pakistan				A	A		A			A
Palestine				A
Panama	A			A
Papua New Guinea					A
Paraguay				A
Peru	A						A
Philippines	A			A	A	A
Qatar	A	A
Russia				A					A			A
San Marino				A
Saudi Arabia	B				A
Serbia	A			A			A
Seychelles				A	A		A
Singapore	A	A
Slovakia				A
South Africa	A		A		A
South Korea	A				A
Sri Lanka				A	A
St. Vincent and the Grenadines				A
Switzerland	B	B	A
Syria				A
Taiwan					A
Thailand	A	A	A		A	A
Tunisia	A			A
Turkey						A
Turkmenistan				A					B
Ukraine					A	A
United Arab Emirates	A			A			B				A
United Kingdom	A	A			A
United States	A	A	A
Uruguay						A
Uzbekistan				A									A
Venezuela				A			A
Vietnam		A		A	A
Zimbabwe				A		A	A	A
World Health Organization	A		A		A

The figures below provide information about the number of vaccine doses that have been administered around the world. We thank Our World in Data for providing free access to the data they collect and their interactive figures which bring the data to life.

To date, five geographic areas (United States, China, European Union, India, and United Kingdom) account for about 75% of the COVID-19 vaccines administered, while representing about 50% of the World population and 53% of confirmed COVID-19 deaths.

February 25, 2021: The National Medical Products Administration in China has approved use of a second COVID-19 vaccine developed by Sinopharm. This is an inactivated vaccine developed in collaboration with the Wuhan Institute of Biologics. Sinopharm reported that the vaccine is 72.51% effective. However, no data from the Phase 3 studies evaluating this vaccine have been released to the public and no study findings have been published in the peer-reviewed scientific literature. Therefore, it is not possible to determine whether this estimate of vaccine efficacy is valid or reliable.

January 2, 2021: The National Medical Products Administration in China has approved use of a COVID-19 vaccine developed by Sinopharm. This is an inactivated vaccine developed in collaboration with the Beijing Institute of Biological Products. Sinopharm reported that the vaccine is 86% effective in preventing all cases of COVID-19 and 100% effective in preventing moderate and severe cases. It is not clear if asymptomatic cases were included in the analyses or if symptomatic cases needed to be confirmed by laboratory testing. In previous reports, the vaccine was reported to be 79.34% effective. The Company stated that the discrepancy between the two estimates was due to differences in study methods used in different countries. Unfortunately, no data from the Phase 3 studies evaluating this vaccine have been released to the public and no study findings have been published in the peer-reviewed scientific literature. Therefore, it is not possible to determine whether the estimates of vaccine efficacy are valid or reliable.